Nama Insights

Amplify Weight Loss Drug & Treatment ETF (THNR)

Health · Amplify ETFs · NYSE

HealthETF
Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund in the Health category. It has $5.78M in assets, an expense ratio of 0.59% and a 1.64% dividend yield. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is…
Assets under management$5.78M
Expense ratio0.59%
CategoryHealth
Dividend yield1.64%
NAV$25.95
Fund familyAmplify ETFs
ExchangeNYSE

Top holdings

The largest positions Amplify Weight Loss Drug & Treatment ETF reports, by weight.

HoldingNameWeight
LLY Eli Lilly and Co 10.07%
NVO Novo Nordisk AS ADR 8.42%
1093.HK CSPC Pharmaceutical Group Ltd 5.82%
AMGN Amgen Inc 5.75%
PFE Pfizer Inc 5.38%
1801.HK Innovent Biologics Inc 5.30%
AZN.L AstraZeneca PLC 5.27%
REGN Regeneron Pharmaceuticals Inc 4.64%
ABBV AbbVie Inc 4.56%
ROP.SW Roche Holding AG Ordinary Shares new 4.56%

Other Health ETFs

Explore live THNR data on Nama Insights →